New guidelines, growth opportunities, and investment in new technologies

Our Press & Policy

Stay up to date with the latest IVD sector news and developments in health policy.

08Jun

BIVDA Press Release - BIVDA responds to G7 Communique on antimicrobial resistance (AMR)

08 Jun, 2021 | Return|

BIVDA responds to G7 Communique on antimicrobial resistance (AMR)

 

BIVDA has responded to the communique published by the attendees at the G7 meeting in Cornwall, pledging to do more to tackle the problem of AMR.

 

Across the world, AMR is responsible for hundreds of thousands of avoidable deaths a year and the numbers are increasing year on year by 4% - and will continue to do so as current antibiotics lose their effectiveness against new and evolving strains of bacteria.

 

Commenting on the announcement, BIVDA Chief Executive Doris-Ann Williams said;

 

“We welcome this communique, and hope that the significant role diagnostics can play in reducing the use of unnecessary antibiotics is not overlooked. Antibiotics have become an essential tool for both managing and preventing infection over the last 100 years but unless we re-think our strategies to use them, then new antibiotics will still be affected by bacterial resistance. Diagnostics should be given the same focus as new drugs so we can develop tests to help direct therapeutic use and avoid the use of antibiotics where possible.”

 

ENDS

 

For more information please contact BIVDA External Affairs Manager jonh@bivda.org.uk

Interested in becoming a member? Join us!

Copyright 2024 BIVDA Ltd is registered in England
Company Number 2687137
Registered Office is 299 Oxford Street (5th floor),
London, W1C 2DZ. VAT Number 563105858